Poly Medicure Q3 Profit Surges 76% Standalone; Eyes Global Growth via Acquisitions

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Poly Medicure Q3 Profit Surges 76% Standalone; Eyes Global Growth via Acquisitions
Overview

Poly Medicure Limited reported robust Q3 FY26 results, with consolidated revenue up 13.83% YoY and consolidated PAT rising 10.70%. Notably, standalone PAT surged an impressive 76.35% YoY. The company also advanced its global strategy by acquiring significant economic rights in Pendracare Group and Medistream SA, marking key M&A milestones.

📉 The Financial Deep Dive

The Numbers:
Poly Medicure Limited showcased strong year-on-year performance for the third quarter ended December 31, 2025 (Q3 FY26).

  • Consolidated Revenue: ₹1188.62 Cr, a rise of 13.83% YoY from ₹1044.17 Cr in Q3 FY25.

  • Consolidated PAT: ₹783.84 Cr, an increase of 10.70% YoY from ₹708.09 Cr in Q3 FY25.

  • Consolidated EPS: ₹7.73, up from ₹7.00 in the prior year.

The standalone performance was even more striking:
  • Standalone Revenue: ₹886.15 Cr, up 30.23% YoY from ₹680.40 Cr in Q3 FY25.

  • Standalone PAT: ₹601.48 Cr, a substantial leap of 76.35% YoY from ₹341.08 Cr in Q3 FY25.

  • Standalone EPS: ₹7.73, a significant increase from ₹5.03 in Q3 FY25.

For the nine-month period ended December 31, 2025 (9M FY26):
  • Consolidated Revenue: Grew 6.59% YoY to ₹34788.89 Cr.

  • Consolidated PAT: Increased 20.98% YoY to ₹25536.32 Cr.

  • Standalone Revenue: Showed marginal growth of 0.16% YoY to ₹25536.32 Cr.

  • Standalone PAT: Increased 23.80% YoY to ₹11339.00 Cr.

The Quality:
The company recognized an exceptional item of ₹6.80 Cr related to a provision for past service cost on gratuity and compensated absences, stemming from the implementation of new Labour Codes. This provision slightly impacted the PAT figures. The significant jump in standalone PAT suggests strong operational efficiencies or improved product mix for the core Indian business, outweighing the marginal standalone revenue growth. Consolidated performance benefits from the diversified revenue streams and potentially the initial consolidation of acquired entities.

The Grill:
(No specific analyst grill or controversial management response was noted in the provided text.)

🚩 Risks & Outlook

Specific Risks:
The acquisitions of Pendracare Group and Medistream SA are subject to provisional accounting, which may lead to adjustments in future periods. Furthermore, the resolution plan for Himalayan Mineral Water Private Limited faces an appeal at NCLAT regarding past statutory liabilities, indicating potential delays or further complications in its finalization. Integration risks associated with the newly acquired European entities, including cultural differences, regulatory compliance, and operational synergy realization, are key areas to monitor. The marginal standalone revenue growth for the nine-month period warrants attention to ensure sustained top-line expansion alongside profitability.

The Forward View:
Investors will be keen to see the finalization of accounting for the recent acquisitions and their contribution to future revenue and profitability. The company's ability to successfully integrate these entities and leverage their market presence in Europe will be critical. Monitoring the outcome of the NCLAT appeal for Himalayan Mineral Water will also be important. Continued strong performance in standalone PAT will be a key indicator of operational strength.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.